Valproic acid: A viable alternative to sodium butyrate for enhancing protein expression in mammalian cell cultures

Biotechnology and Bioengineering

Volumn 101, Issue 1, 2008, Pages 182-189

  Backliwal, Gaurav ^a   Hildinger, Markus ^b   Kuettel, Ivan ^a   Delegrange, Fanny ^a   Hacker, David L ^a   Wurm, Florian M ^a  

^a EPFL   (Switzerland)

^b EXCELLGENE SA   (Switzerland)

Author keywords

CHO; DNMT; HDAC; HEK; Inhibitor; Transfection

Indexed keywords

ANIMAL CELL CULTURE; ANTIBODIES; ARSENIC COMPOUNDS; CELLS; CHLORINE COMPOUNDS; CONCENTRATION (PROCESS); COST EFFECTIVENESS; CYTOLOGY; FOOD ADDITIVES; GENE EXPRESSION; MAMMALS; MONOCLONAL ANTIBODIES; NUCLEIC ACIDS; ORGANIC ACIDS; SODIUM;

ADDITIVE EFFECTS; CELL LINES; CELLULAR ACTIVITIES; CHINESE-HAMSTER OVARY; CHO; DNMT; HDAC; HEK; HISTONE DEACETYLASE INHIBITORS; HUMAN EMBRYONIC KIDNEY; INHIBITOR; MAMMALIAN CELL CULTURES; MAMMALIAN CELLS; METHYL TRANSFERASES; OPTIMUM CONCENTRATION; PAIR-WISE COMBINATIONS; PROTEIN EXPRESSIONS; RECOMBINANT MONOCLONAL ANTIBODY; RECOMBINANT PROTEIN PRODUCTIONS; REPORTER PROTEIN; SODIUM BUTYRATE; TRANSFECTION; TRANSIENT GENE EXPRESSIONS; VALPROIC ACID;

CELL CULTURE;

BUTYRIC ACID; DNA METHYLTRANSFERASE INHIBITOR; HISTONE DEACETYLASE INHIBITOR; MONOCLONAL ANTIBODY; VALPROIC ACID;

ANIMAL CELL; ARTICLE; CELL STRAIN HEK293; CHO CELL; CONTROLLED STUDY; COST EFFECTIVENESS ANALYSIS; DRUG EFFECT; EMBRYO; GENETIC TRANSFECTION; HUMAN; HUMAN CELL; MAMMAL CELL; NONHUMAN; PROTEIN EXPRESSION; TRANSIENT EXPRESSION;

ANTIBODIES, MONOCLONAL; BUTYRATES; CELL LINE; DOSE-RESPONSE RELATIONSHIP, DRUG; GENE EXPRESSION; HUMANS; KIDNEY; PROTEIN ENGINEERING; VALPROIC ACID;

CRICETULUS GRISEUS; MAMMALIA;

EID: 50049130165     PISSN: 00063592     EISSN: 10970290     Source Type: Journal    
DOI: 10.1002/bit.21882     Document Type: Article

References (33)

1. Backliwal G, Hildinger M, Hasija V, Wurm FM. 2008. High-density transfection with HEK-293 cells allows doubling of transient titers and removes need for a priori DNA complex formation with PEL Biotechnol Bioeng 99(3):721-727.
2. Baldi L, Hacker DL, Adam M, Wurm FM. 2007. Recombinant protein production by large-scale transient gene expression in mammalian cells: State of the art and future perspectives. Biotechnol Lett 29(5):677-684.
3. Baylin SB. 2005. DNA methylation and gene silencing in cancer. Nat Clin Pract Oncol 2 (Suppl 1): S4-11.
4. Bird AP, Wolffe AP. 1999. Methylation-induced repression-Belts, braces, and chromatin. Cell 99(5):451-454.
5. Chen G, Yuan PX, Jiang YM, Huang LD, Manji HK. 1999. Valproate robustly enhances AP-1 mediated gene expression. Brain Res Mol Brain Res 64(1):52-58.
6. Chen ZY, He CY, Meuse L, Kay MA. 2004. Silencing of episomal transgene expression by plasmid bacterial DNA elements in vivo. Gene Ther 11(10):856-864.
7. Choi KH, Basma H, Singh J, Cheng PW. 2005. Activation of CMV promoter-controlled glycosyltransferase and beta-galactosidase glycogenes by butyrate, tricostatin A, and 5-aza-2′-deoxycytidine. Glycoconj J 22(1-2):63-69.
8. Chuang JC, Yoo CB, Kwan JM, Li TW, Liang G, Yang AS, Jones PA. 2005. Comparison of biological effects of non-nucleoside DNA methylation inhibitors versus 5-aza-2′-deoxycytidine. Mol Cancer Ther 4(10):1515-1520.
9. Davie JR. 2003. Inhibition of histone deacetylase activity by butyrate. J Nutr 133 (7 Suppl): 2485S-2493S.
10. De Jesus M, Girard P, Bourgeois M, Baumgartner G, Jacko B, Amstutz H, Wurm FM. 2004. TubeSpin satellites: A fast track approach for process development with animal cells using shaking technology. J Biochem Eng 17(3):217-223.
11. Gorman CM, Howard BH, Reeves R. 1983. Expression of recombinant plasmids in mammalian cells is enhanced by sodium butyrate. Nucleic Acids Res 11(21):7631-7648.
12. Gottlicher M, Minucci S, Zhu P, Kramer OH, Schimpf A, Giavara S, Sleeman JP, Lo Coco F, Nervi C, Pelicci PG. Heinzel T. 2001. Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells. EMBO J 20(24):6969-6978.
13. Hong K, Sherley J, Lauffenburger DA. 2001. Methylation of episomal plasmids as a barrier to transient gene expression via a synthetic delivery vector. Biomol Eng 18(4):185-192.
14. Johnstone RW. 2002. Histone-deacetylase inhibitors: Novel drugs for the treatment of cancer. Nat Rev Drug Discov 1(4):287-299.
15. Kramer OH, Zhu P, Ostendorff HP, Golebiewski M, Tiefenbach J, Peters MA, Brill B, Groner B, Bach I, Heinzel T, Göttlicher M. 2003. The histone deacetylase inhibitor valproic acid selectively induces proteasomal degradation of HDAC2. EMBO J 12(13):3411-3420.
16. Kurz EU, Wilson SE, Leader KB, Sampey BP, Allan WP, Yalowich JC, Kroll DJ. 2001. The histone deacetylase inhibitor sodium butyrate induces DNA topoisomerase II alpha expression and confers hypersensitivity to etoposide in human leukemic cell lines. Mol Cancer Ther 1(2):121-131.
17. Leschelle X, Delpal S, Goubern M, Blottiere HM, Blachier F. 2000. Butyrate metabolism upstream and downstream acetyl-CoA synthesis and growth control of human colon carcinoma cells. Eur J Biochem 267(21):6435-6442.
18. Lyko F, Brown R. 2005. DNA methyltransferase inhibitors and the development of epigenetic cancer therapies. J Natl Cancer Inst 97(20):1498-1506.
19. Meissner P, Pick H, Kulangara A, Chatellard P, Friedrich K, Wurm FM. 2001. Transient gene expression: Recombinant protein production with suspension-adapted HEK293-EBNA cells. Biotechnol Bioeng 75(2): 197-203.
20. Muller N, Girard P, Hacker DL, Jordan M, Wurm FM. 2005. Orbital shaker technology for the cultivation of mammalian cells in suspension. Biotechnol Bioeng 89(4):400-406.
21. Pham PL, Kamen A, Durocher Y. 2006. Large-scale transfection of mammalian cells for the fast production of recombinant protein. Mol Biotechnol 34(2):225-237.
22. Pick HM, Meissner P, Preuss AK, Tromba P, Vogel H, Wurm FM. 2002. Balancing GFP reporter plasmid quantity in large-scale transient transfections for recombinant anti-human Rhesus-D IgG1 synthesis. Biotechnol Bioeng 79(6):595-601.
23. Qin L, Ding Y, Pahud DR, Chang E, Imperiale MJ, Bromberg JS. 1997. Promoter attenuation in gene therapy: Interferon-gamma and tumor necrosis factor-alpha inhibit transgene expression. Hum Gene Ther 8(17):2019-2029.
24. Reddy P, Rasmussen BD. Immunex Corporation (Thousand Oaks, CA), assignee. 2005. Methods for producing proteins in cultured cells. USA patent 6,890,736.
25. Riu E, Chen ZY, Xu H, He CY, Kay MA. 2007. Histone modifications are associated with the persistence or silencing of vector-mediated transgene expression in vivo. Mol Ther 15(7):1348-1355.
26. Silva MF, Ruiter JP, Overmars H, Bootsma AH, van Gennip AH, Jakobs C, Duran M, Tavares de Almeida I, Wanders RJ. 2002. Complete beta-oxidation of valproate: Cleavage of 3-oxovalproyl-CoA by a mitochondrial 3-oxoacyl-CoA thiolase. Biochem J 362(Pt 3):755-760.
27. Stamatoyannopoulos G, Blau CA, Nakamoto B, Josephson B, Li Q, Liakopoulou E, Pace B, Papayannopoulou T, Brusilow SW, Dover G. 1994. Fetal hemoglobin induction by acetate, a product of butyrate catabolism. Blood 84(9):3198-3204.
28. Stettler M, Jaccard N, Hacker D, De Jesus M, Wurm FM, Jordan M. 2006. New disposable tubes for rapid and precise biomass assessment for suspension cultures of mammalian cells. Biotechnol Bioeng 95(6): 1228-1233.
29. Stresemann C, Brueckner B, Musch T, Stopper H, Lyko F. 2006. Functional diversity of DNA methyltransferase inhibitors in human cancer cell lines. Cancer Res 66(5):2794-2800.
30. Suzuki M, Kasai K, Saeki Y. 2006. Plasmid DNA sequences present in conventional herpes simplex virus amplicon vectors cause rapid transgene silencing by forming inactive chromatin. J Virol 80(7):3293-3300.
31. Villar-Garea A, Fraga MF, Espada J, Esteller M. 2003. Procaine is a DNA-demethylating agent with growth-inhibitory effects in human cancer cells. Cancer Res 63(16):4984-4989.
32. Wurm FM. 2004. Production of recombinant protein therapeutics in cultivated mammalian cells. Nat Biotechnol 22(11):1393-1398.
33. Wurm F, Bernard A. 1999. Large-scale transient expression in mammalian cells for recombinant protein production. Curr Opin Biotechnol 10(2):156-159.